Sign in
Not yet recruitingPhase 2

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study

Key facts

Who runs it
Central Adelaide Local Health Network Incorporated
Where
Australia3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
May 2026
Planned end
Jul 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sirolimus (RAPAMUNE)
  • Influenza vaccine (Sequiris Fluad Quad)
  • RSV vaccine (Pfizer Abrysvo)
Record updated
14 May 2026

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • End-stage kidney disease requiring in-centre haemodialysis three times per week as kidney replacement therapy
  • Aged >60 years

Who cannot take part

  • Current use of immunosuppressive medications, including:; Oral steroid at a dose equivalent of 5 mg/day prednisolone or greater; Mycophenolate mofetil; Azathioprine; Calcineurin inhibitors; mTOR inhibitors
  • Recent use of intravenous immunosuppressive medications (<6 months), including:; T-cell depleting agents (e.g. anti-thymocyte globulin); B-cell depleting agents (e.g. rituximab); Cyclophosphamide
  • Has a history of problems with side-effects associated with sirolimus use including; Angioedema; Active/recent opportunistic infection; Current or prior interstitial lung disease, non-infectious pneumonitis, organising pneumonia, or pulmonary fibrosis; Clinically significant pleural effusion or pericardial effusion; Active non-healing wounds, chronic skin ulcers, or planned major surgery/procedures; Current malignancy or recent malignancy with high recurrence risk; Severe or uncontrolled hyperlipidaemia; History of rhabdomyolysis; Severe hepatic impairment
  • Ongoing use of strong CYP3A4/P-gp inhibitors or inducers including; Inhibitors: Ketoconazole, Voriconazole, Itraconazole, Telithromycin, Clarithromycin; Inducers: Rifampicin, Rifabutin
  • Recent infection (<6 months) with proven Influenza A, Influenza B, or RSV
  • Known allergy to or intolerance of sirolimus (rapamycin) or the contents of the influenza or RSV vaccine
  • Aged <60 years
  • Alternative haemodialysis regimens (e.g. twice-weekly haemodialysis, second-daily home haemodialysis)
  • Unable or unwilling to provide informed consent to participate in the trial

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will investigate dialysis recipients' responses to important vaccines.

Read full original descriptionShow less

Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.

The 4 groups in the trial

  • ControlExisting treatment, for comparison

    Influenza and RSV vaccination without additional treatment

    Treatment: Influenza vaccine (Sequiris Fluad Quad) and RSV vaccine (Pfizer Abrysvo)

  • Pre-vaccine sirolimus groupTreatment being tested

    Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks after completing sirolimus course.

    Treatment: Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), and RSV vaccine (Pfizer Abrysvo)

  • Peri-vaccine sirolimus groupTreatment being tested

    Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 1 week after commencing sirolimus course.

    Treatment: Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), and RSV vaccine (Pfizer Abrysvo)

  • Post-vaccine sirolimus groupTreatment being tested

    Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks prior to commencing sirolimus course.

    Treatment: Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), and RSV vaccine (Pfizer Abrysvo)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Vaccination Response Modulation With a Targeted Rapamycin Protocol (VON TRAPP) Study
Record updated
14 May 2026